Browse All

Current Filters

CLEAR FILTER x

TITLE

Switching to Subcutaneous Zilucoplan from Intravenous Complement Component 5 Inhibitors in Myasthenia Gravis: Patient Preference and Satisfaction from a Phase 3b Study

Author:Freimer, Miriam   Desai, Urvi   Govindarajan, Raghav   Kang, Min K.   Khan, Shaida   Khatri, Bhupendra   Levine, Todd   Macwan, Samir   Shieh, Perry B.   Weiss, Michael D.   Bloemers, Jos   Boroojerdi, Babak   Delicha, Eumorphia Maria   Lavrov, Andreea   Singh, Puneet   Howard Jr., Ja   

Session Name:P1: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis 1  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P1.009  

Author Institution:The Ohio State University Wexner Medical Center, Columbus, OH, USA, Columbus, OH  Atrium Health, Wake Forest University, Charlotte, NC, USA, Charlotte, NC  HSHS St. Elizabeth’s Hospital, O’Fallon, IL, USA, O'Fallon, IL  University of California, San Francisco, San Francisco, CA, USA, San Francisco, CA  UT Southwestern Medical Center, Dallas, TX, USA, Dallas, TX  The Regional MS Center and Center for Neurological Disorders, Milwaukee, WI, USA, Milwaukee, WI  HonorHealth Neurology, Bob Bové Neuroscience Institute, Scottsdale, AZ, USA, Scottsdale, AZ  Eisenhower Health, Rancho Mirage, CA, USA, Rancho Mirage, CA  University of California, Los Angeles, Los Angeles, CA, USA, Los Angeles, CA  University of Washington Medical Center, Seattle, WA, USA, Seattle, WA  UCB, Brussels, Belgium, Brussels, Belgium  UCB, Monheim, Germany, Monheim, Germany  UCB, Braine-l’Alleud, Belgium, Braine-l’Alleud, Belgium  UCB, Slough, UK, Slough , United Kingdom  The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, Chapel Hill, NC  

Real-World Treatment Outcomes in Patients with Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis Who Transitioned from Efgartigimod to Ravulizumab